ArticleMolecular medicine reports2018
Functional role of miR-27b in the development of gastric cancer.
Article in Molecular medicine reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 17 citations in OpenAlex.
- miR-27b-5p targets RAB27A to regulate exosome secretion and migration of pancreatic cancer cells.Translational cancer research · 2026Article
- Association of Selected miRNAs (hsa-miR-27b, hsa-miR-128-3p, hsa-miR-145-5p, hsa-miR-552-3p) with HER2 Status and Chromosome 17 Centromere Copy Number Increase in Gastric Cancer.International journal of molecular sciences · 2026Article
- Increased Expression ofIranian journal of public health · 2025Article
- Expression and effect of miR‑27b in primary liver cancer.Oncology letters · 2024Article
- microRNA-27b regulates hepatic lipase enzyme LIPC and reduces triglyceride degradation during hepatitis C virus infection.The Journal of biological chemistry · 2022Article
- [Progress in the Mechanism of Lymphangiogenesis and Lymphatic Metastasis of Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2021Review
- MicroRNAs are involved in the development and progression of gastric cancer.Acta pharmacologica Sinica · 2021Review
- Combined targeting of vascular endothelial growth factor C (VEGFC) and P65 using miR-27b-3p agomir and lipoteichoic acid in the treatment of gastric cancer.Journal of gastrointestinal oncology · 2021Article
- A predictive model for assessing prognostic risks in gastric cancer patients using gene expression and methylation data.BMC medical genomics · 2021Article
- Review
- Effect of miR-27b-5p on apoptosis of human vascular endothelial cells induced by simulated microgravity.Apoptosis : an international journal on programmed cell death · 2020Article
- Literature-Based Enrichment Insights into Redox Control of Vascular Biology.Oxidative medicine and cellular longevity · 2019Review
- Downregulation miR-539 is associated with poor prognosis of gastric cancer patients and aggressive progression of gastric cancer cells.Cancer biomarkers : section A of Disease markers · 2019Article
- Up-Regulated MicroRNA-27b Promotes Adipocyte Differentiation via Induction of Acyl-CoA Thioesterase 2 Expression.BioMed research international · 2019Article
- RETRACTED: miR-27b Targets HOXB8 to Inhibit Malignant Behaviors of Osteosarcoma.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous studies have demonstrated that microRNAs (miRNAs/miRs) act as tumor suppressors or oncogenes during multiple processes in cancer. It has been observed that miR‑27b may act as a tumor‑suppressor and was significantly downregulated in a number of types of cancer. However, the functions of miR‑27b in gastric cancer (GC) remain unclear. The present study aimed to investigate the functional role of miR‑27b in the progression of GC. The downregulation of miR‑27b in human GC plasma was confirmed using miRNA microarray and reverse transcription‑quantitative polymerase chain reaction analyses. The association between circulating miR‑27b expression and clinicopathological features of GC was analyzed and the results demonstrated that the level of circulating miR‑27b was significantly correlated with GC differentiation. Receiver operating characteristic curve analysis identified that the plasma level of miR‑27b may be a potential biomarker for differentiating patients with GC from healthy controls. In order to investigate the effect of miR‑27b on GC cell behavior, miR‑27b was overexpressed using miR‑27b mimics, and it was observed that miR‑27b was able to inhibit cell proliferation and induce apoptosis in SGC7901 cells. Previous studies have demonstrated that vascular endothelial growth factor C (VEGFC) is a target of miR‑27b, and the results of the present study were consistent with these reports. Taken together, the results of the present study indicated that miR‑27b may act as a potential biomarker for differentiating patients with GC from healthy controls, and serve as a tumor suppressor in GC by targeting VEGFC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.